Fulcrum Therapeutics resumed with a Buy at Stifel

Stifel resumed coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $20 price target Recent 12mg data already support a “compelling profile” for pociredir and the “bar” for the full 20mg cohort is low, argues the analyst, who adds that there’s “a blockbuster opportunity that supports meaningful upside” even as Fulcrum’s trial population and criteria exists today.